The Holistic Pharmacy Approach To 340B Patient Support

September 8, 2025340B, Bedside Prescription Delivery, Contract Pharmacy, Drug Manufacturer Restrictions, Meds To Beds, Patient Eligibility, PBM, Readmissions Reduction, Retail / Outpatient Pharmacy, Specialty Drugs, Specialty Pharmacy, Uncategorized, Value-Based Care

How to make Pharmacy “The Easy Part” of the patient experience. Anyone who’s ever been a hospital patient, or patient caregiver, knows that the mental strain of a serious illness can often match the negative impact of the physical trauma. Particularly when an illness is chronic and/or long-term, the stress involved in managing the details … Read More

Why A 340B Hospital Should Own A Specialty Pharmacy. Why Not.

July 8, 2025340B ESP, Bedside Prescription Delivery, Contract Pharmacy, PBM, Readmissions Reduction, Retail / Outpatient Pharmacy, Specialty Drugs, Specialty Pharmacy, TPA / TPAs

Before we begin, we’re going to be honest with you. A significant component of VytlOne’s business is guiding 340B health systems through the process of building, accrediting, funding, launching and managing on-campus specialty pharmacies. Many times in this space, we’ve maintained that every 340B hospital should consider owning a specialty pharmacy. We’re currently in the … Read More

How Recent 340B Changes Impact Specialty Pharmacies In 2025

June 4, 2025340B, Compliance, Covered Entities, Drug Manufacturer Restrictions, News Updates, Readmissions Reduction, Specialty Drugs, Specialty Drugs, Specialty Pharmacy

The evolving legal and legislative landscape surrounding the 340B Drug Pricing Program has significant implications for hospitals’ specialty pharmacies. Here’s a breakdown of the new developments and their likely impacts: Recent 340B changes and their impact on specialty pharmacies 1. 340B contract pharmacy restrictions Drug manufacturers have increasingly restricted the use of contract pharmacies, especially … Read More

Navigating 340B Program Changes in 2025

April 1, 2025340B, 340B ESP, Audit, Compliance, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, News Updates, Specialty Drugs, Specialty Pharmacy

Maximizing pharmacy’s role in your hospital’s revenue cycle The 340B landscape continues to evolve rapidly, with ongoing manufacturer restrictions, new compliance hurdles, and increasing financial pressures on covered entities. The average 340B-eligible hospital loses a substantial amount of money due to drug manufacturer restrictions on the program. Recent estimates indicate that hospitals and clinics collectively … Read More

J&J’s Numbers Reveal The Fallacy Of 340B Price Restrictions

October 25, 2024340B, Covered Entities, Drug Manufacturer Restrictions, PBM, Specialty Drugs, Specialty Pharmacy

POST OUTLINE Introduction: Overview Review of Johnson & Johnson’s drug rebate payments in 2023 J&J’s 2023 profit margin Johnson & Johnson’s real rebate problem 340B and the drug industry as a whole Estimated percentage of drug sales supporting 340B health systems Why the actual number is lower than reported The importance of 340B savings & … Read More

Overcome 340B Restrictions With Software And Human Insight

August 28, 2024340B, 340B ESP, Bedside Prescription Delivery, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, Meds To Beds, Overview, Specialty Drugs, Specialty Pharmacy, TPA / TPAs

POST OUTLINE PHASE ONE: Organizing 340B data, coordinating teams Connecting and educating 340B system providers Requalifying all eligible, but unreimbursed, 340B scripts Retrieving 340B eligible-script data Establishing communication lines between internal and external 340B teams Why specialized software is essential for successful 340B programs The central problem with most 340B programs’ data Why 340B software … Read More

Optimize Your Health System’s Patient Care & ROI With 340B

August 7, 2024340B, 340B ESP, Compliance, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, Meds To Beds, Patient Eligibility, Prescription Discounts, Readmissions, Retail / Outpatient Pharmacy, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy, TPA / TPAs

Far too many 340B hospitals overlook pharmacy’s overall potential in their health systems’ revenue cycles. Below is a graphic overview of VytlOne’s integrated approach to optimizing a health system’s pharmacy services, savings and revenue. In 340B support alone, we’ve generated over $500 million for the hospitals we serve — revenue those systems have used to … Read More

Is Your 340B Vendor A Partner Or A Parasite?

May 16, 2024340B, Covered Entities, Patient Eligibility, Retail / Outpatient Pharmacy, Specialty Drugs, Specialty Pharmacy

Why 340B vendors charging Percentage Of Revenue is wrong. The United States Congress established the 340B statute in 1992 to help non-profit hospitals fill-in the often-backbreaking revenue gaps inherent to their business models — enabling covered entities to replenish eligible prescriptions at significant savings. Savings which they can then pass-along to their patients, many of … Read More

340B Outlook For 2024: Change. Change. And More Change.

April 19, 2024340B, 340B ESP, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, News Updates, Specialty Drugs, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy

POST OUTLINE 1) What we’ve learned. What it means for your 340B program. Overview of VytlOne 340B Team experience and successes Dealing with frequent, unexpected changes 2) Potential 340B developments for 2024 National legislation prospects State regulatory changes 3) Legislative & court updates Bill introduced into House Of Representatives Supreme Court overturns 340B restriction cuts … Read More

The Case for Onsite Specialty Pharmacies in 340B Hospitals

April 4, 2024340B, 340B ESP, Bedside Prescription Delivery, Compliance, Covered Entities, Drug Manufacturer Restrictions, Meds To Beds, Prescription Discounts, Requirements, Specialty Drugs, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy

Why a Specialty Pharmacy? (Overview) As chronic illnesses become increasingly common in the United States, the number of specialty medications for managing these conditions has skyrocketed. According to a report by The American Hospital Association, the number of Americans with chronic medical conditions will grow by a projected 9% between 2020 and 2030, an increase … Read More